Efficacy of ergonovine in preventing hemorrhage of cesarean section in high-risk pregnant women

Objective To evaluate the curative effect and safety of ergonovine in preventing bleeding during and after cesarean section in high risk pregnant women. Methods One thousand and seventy-four parturients with high risk factors of bleeding who underwent cesarean section in 16 hospitals of China were collected from February to June 2017. Patients were divided into three groups according to the use of different uterine contraction agents: group I (384 cases, oxytocin plus ergonovine were injected intraoperatively, oxytocin was injected after operation), group II (340 cases, oxytocin plus ergonovine were injected intraoperatively, ergonovine was injected after operation), control group (350 cases, oxytocin was injected intraoperatively and after operation). The bleeding volume and side effects of the operation, 2 h and 24 h after operation were analyzed and compared. Analysis of variance or Chi-square test was used for statistical analysis. Results In group II, the amount of blood loss of the operation, 2 h and 24 h after operation were (400.09±203.82) ml, (31.76±27.83)ml, (60.74±55.27)ml, respectively, which were significantly less than those in group I (451.33±441.43) ml, (66.30±43.08)ml, (83.62±56.89)ml, (P<0.05). The incidence rate of the patients used uterine contraction agent in group II was 5.29% (18 cases), which was smaller than those in group I (23.18%, 89 cases) and in the control group (29.14%, 102 cases), q=3.90 and 4.32, respectively, and P less than 0.05. Conclusion Ergonovine was effective and safe for high risk pregnant women with cesarean section to prevent intraoperative hemorrhage and postoperative hemorrhage, but close attention should be paid to the adverse drug reaction. Key words: Ergonovine; Cesarean section; Pregnancy, high-risk